China approves ecnoglutide for chronic weight management

China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for chronic weight management in adults with overweight or obesity, Sciwind Biosciences announced March 6, 2026 ^[1]. The approval gives ecnoglutide a second use in China, on top of an earlier approval for type 2 diabetes, and adds another domestic option competing with semaglutide-based products sold there ^[1].

Sciwind describes ecnoglutide as the world's first approved "cAMP-biased" GLP-1 receptor agonist for weight management, a drug designed to activate one internal signaling pathway (cAMP) while limiting another (β-arrestin recruitment), which the company says distinguishes it from older, "non-biased" GLP-1 drugs like semaglutide ^[1]. Whether this mechanism produces meaningfully different real-world outcomes for patients has not been independently confirmed outside company-sponsored trials, based on the material provided.

The approval rests on the Phase 3 SLIMMER trial in Chinese adults with overweight or obesity. At the highest dose tested, 2.4 mg, participants lost an average of 15.4% of body weight at 48 weeks, or 15.1% after subtracting the placebo group's loss ^[1]. Nearly 93% of people on ecnoglutide reached at least 5% weight loss, almost seven times the rate seen with placebo, while 79.6% lost at least 10% and 63.5% lost at least 15% ^[1]. Sciwind says weight loss was still continuing at week 48 without leveling off, suggesting longer treatment might produce more loss, though the trial did not run past that point ^[1].

The study also reported improvements in waist size, blood pressure, cholesterol, blood sugar measures, and insulin resistance, plus a drop in uric acid levels of up to 54.3 µmol/L ^[1]. Among participants who started with high liver fat (at least 8%), those on the 2.4 mg dose saw liver fat drop by an average of 53.1% at week 40, along with reductions in liver enzyme levels across all doses ^[1]. The trial results were published in The Lancet Diabetes & Endocrinology in June 2025 and were presented at meetings of the American Diabetes Association and the European Association for the Study of Diabetes ^[1].

Why it matters for patients

Ecnoglutide is not approved by the U.S. Food and Drug Administration and is not sold in the United States, so this news does not change what's available to American patients right now. Nothing in Sciwind's announcement indicates a U.S. filing timeline or plans, based on the material provided.

The development is still relevant as a sign of how crowded the global GLP-1 market is becoming. China now has multiple approved GLP-1 obesity drugs competing with semaglutide products, which mirrors pressure building in other markets, including the U.S., where tirzepatide (Mounjaro/Zepbound) and newer entrants like orforglutide compete with semaglutide (Ozempic/Wegovy/Rybelsus). More competition abroad can eventually shape pricing, manufacturing capacity, and drugmakers' investment decisions worldwide, though any effect on U.S. prices or supply is not established by these sources.

It's also worth noting that the efficacy figures come from a company-issued release describing its own trial, and results were generated in a Chinese study population, not U.S. patients. Long-term safety data beyond the 48-week trial period, and any independent comparison with FDA-approved drugs in a U.S. population, are not addressed in the available material.

What happens next

Sciwind says ecnoglutide has now completed regulatory approval in China for both weight management and type 2 diabetes ^[1]. No specific dates for expansion to other countries, including the United States, are given in the source material.